Moderna, Inc.

Moderna, Inc.

Moderna, Inc.

Overview
Date Founded

2010

Headquarters

320 BENT STREET, CAMBRIDGE, MA, 02141

Type of Company

Public

Employees (Worldwide)

830

Industries

Biotechnology
Medical Support Services
Hospitals & Patient Services

Company Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Moderna, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Director & Chief Executive Officer

President

Chief Financial Officer

General Counsel & Corporate Secretary

Chief Development Officer

Ph.D.Chief Scientific Officer

Chief Digital & Operational Excellence Officer

Chief Medical Officer

Chief Technical Operations & Quality Officer

Board of Directors

Co-Founder at Moderna, Inc.

Director & Chief Executive Officer at Moderna, Inc.

Investment Team at General Catalyst LLC

Emeritus Professor of Medicine at Stanford University - School of Medicine

Founder at Fate Therapeutics, Inc.

Member-Sports Board at The University of Nottingham

Executive Vice President & Treasurer at Massachusetts Institute of Technology

Former President, Chief Executive Officer & Director, NPS Pharmaceuticals, Inc at NPS Pharmaceuticals, Inc.

Managing Partner at Flagship Pioneering

Paths to Moderna, Inc.
Potential Connections via
Relationship Science
You
Moderna, Inc.
Owners & Shareholders
Details Hidden

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Details Hidden

Thélème is an active manager which manages a global long/short equity strategy fund, investing primarily in US equities and also in European, Asian and emerging market equities. The firm does not plan to take activist positions.

Details Hidden

Banque Pictet & Cie constructs portfolios of investments in large companies with stable earnings, balanced by shorter-term positions in stocks that have been mispriced or have the potential for recovery for bonds and equities. The fixed-income component generally includes core holdings of investment-grade sovereign debt and corporate bonds, complemented by opportunistic investments in high-yield corporate bonds and local currency emerging-market debt. Banque Pictet & Cie's fund mandates are managed by the team responsible for discretionary portfolios of mutual funds, exchange-traded funds and other pooled vehicles, operating on the principle of open architecture, selecting best-in-class Pictet or external funds. The firm also offers special mandates, such as absolute return mandates, which aim to take advantage of volatile markets without being tied to a relative benchmark. Their momentum strategy mandate invests in the asset class with the best relative momentum to outperform equity markets over a rolling three-year horizon.

Recent Transactions
Details Hidden

Moderna, Inc. issued USD Common Stock

Details Hidden

Moderna, Inc. issued USD Common Stock

Details Hidden

Moderna, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onModerna, Inc. issued USD Common Stock

Legal Advisor

Advised onModerna, Inc. issued USD Common Stock

Underwriter

Advised onModerna, Inc. issued USD Common Stock

Legal Advisor

Advised onModerna, Inc. issued USD Common Stock

Associate

Advised onModerna, Inc. issued USD Common Stock

Global Chair, Mergers & Acquisitions

Advised onModerna, Inc. issued USD Common Stock

Advisors & Consultants
Consultant

Professor at Harvard University

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

The Bill & Melinda Gates Foundation was formed in 1997 as the William H. Gates Foundation. In 1999, the foundation was renamed the Bill & Melinda Gates Foundation. The Bill & Melinda Gates Foundation Trust was created in January 2000 through the merger of the Gates Learning Foundation, which worked to expand access to technology through public libraries and the William H. Gates Foundation, which focused on improving global health. The foundation participates in preventive approaches and collaborative endeavors with government, philanthropic and not-for-profit partners. Priority is given to grants that leverage additional support and serve as a catalyst for long-term, systemic change. The foundation also provides funds to promote greater equity in global health, education and public libraries. Through their partnerships in communities across the US, the Bill & Melinda Gates Foundation is committed to raising the high school graduation rate and helping all students, regardless of race or family income. The foundation is headquartered in Seattle, Washington.

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Key Stats and Financials As of 2019
Market Capitalization
$36.7B
Total Enterprise Value
$5.5B
Earnings Per Share
$-1.55
Debt TEV
0.02x
TEVNet Income
-10.7x
Enterprise Value / Sales
91.39x
Total Equity
$1.17B
Total Debt
$136M
EBITDAMargin
-854.85%
EBITDA
$-515M
Net Profit
$-514M
Revenue
$60.2M
Three Year Compounded Annual Growth Rate Of Revenue
-17.8%
Non-Profit Donations & Grants
Investors
Details Hidden

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Details Hidden

Arrowmark Partners (Venture Capital) invests companies located in US. The firm targets companies operating in the fields of wide range of sectors. They provides financing for early and growth stages.

Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Suppliers
mRNA RiboTherapeutics, Inc. Biotechnology | Madison, WISCONSIN

mRNA RiboTherapeutics, Inc. provides products and technology for making and using ribonucleic acid for translation in cells for clinical research and therapeutics. It offers products for MRNA production in vitro transcription, post-transcriptional capping, co--transcriptional capping, post-transcriptional tailing, modified NTP in vitro transcription, mRNA decapping, and RNase inhibition. The company is headquartered in Madison, WI.

Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Lonza Group AG Pharmaceuticals | Basel, Che

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Competitors
GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Amicus Therapeutics, Inc. Pharmaceuticals - Cranbury, New Jersey

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Cranbury, NJ.

Takeda Pharmaceutical Co., Ltd. Pharmaceuticals - Osaka, Japan

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Moderna, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Moderna, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Moderna, Inc..